2-正丁基-5-乙基噻吩 | 54411-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 2-正丁基-5-乙基噻吩
• 中文别名: 2-正丁基-5-乙噻吩
• 英文名称: 2-butyl-5-ethyl-thiophene
• 英文别名: 2-butyl-5-ethylthiophene
• CAS: 54411-06-2
• 化学式: C₁₀H₁₆S
• mdl: MFCD00053118
• 分子量: 168.303
• InChiKey: ORAPMLHUSQJCQH-UHFFFAOYSA-N

物化性质

• 沸点：
  218.8±9.0 °C(Predicted)
• 密度：
  0.947±0.06 g/cm3(Predicted)
• LogP：
  4.942 (est)
• 保留指数：
  1222;1224;1222;1224
• 稳定性/保质期：
  如果按照规格正确使用和储存，则不会分解，没有已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2934999090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2-Butyl-5-Ethylthiophene
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 168,3 g/mol
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid
breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为产物：
  描述：

  (E)-2-庚烯醛 以 aq. phosphate buffer 为溶剂， 反应 2.17h， 生成 2-正丙基呋喃 、 2,5-二丙基噻吩 、 2-正丁基-5-乙基噻吩 、 2-butyl-5-propylthiophene
  参考文献：
  名称：

  葡萄糖，谷胱甘肽和脂肪醛的加热模型系统中初始反应中间体的表征。

  摘要：

  为了了解脂质降解对肉味风味素的美拉德形成的影响，通过以下方法鉴定了葡萄糖-谷胱甘肽与己醛，（E）-2-庚烯或（E，E）-2,4-癸二烯醛的模型系统中的初始反应中间体HPLC-MS和通过NMR。除Amadori化合物外，还发现了通过将巯基加成到羰基或共轭的烯键上的半缩醛和噻唑烷。所有中间体的浓度随反应时间而增加，而具有谷胱甘肽部分的中间体的降解则有助于半胱氨酰甘氨酸形成噻唑烷。不饱和醛（E）-2-庚醛和（E，E）-2,4-癸二醛对谷胱甘肽显示出对葡萄糖的高反应性，比从葡萄糖中产生更高水平的中间体化合物。加热制备的中间体可逆地释放出原始醛，导致由逆醛醇，氧化等形成的各种化合物与H2S和NH3反应。其中，首次提出了包括3-壬烯-2-酮，2-己酰基呋喃和六个二烷基噻吩（例如2-乙基-5-（1-甲基丁基）噻吩）的形成途径。

  DOI：

  10.1016/j.foodchem.2019.125482

文献信息

• [EN] LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS<br/>[FR] COMPOSÉS LACTAMES EN TANT QU'AGONISTES SÉLECTIFS DU RÉCEPTEUR EP4 POUR L'UTILISATION DANS LE TRAITEMENT DE MALADIES ET D'ÉTATS À MÉDIATION PAR EP4
  申请人：CAYMAN CHEMICAL CO INC

  公开号：WO2014144610A1

  公开（公告）日：2014-09-18

  Disclosed herein are compounds of formula (I) wherein L1, L2, L3, R1, R4, R5, and R6 are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

  披露了公式(I)的化合物，其中L1、L2、L3、R1、R4、R5和R6如说明书定义。公式(I)的化合物是EP4激动剂，可用于治疗青光眼、骨质疏松症、骨折、牙周骨丢失、骨科植入物、脱发、神经性疼痛及相关疾病。还描述了药物组合物和治疗条件或疾病的方法。
• Isoprenyl Compounds and Methods Thereof
  申请人：Stock Jeffry B.

  公开号：US20100184768A1

  公开（公告）日：2010-07-22

  Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.

  除其他事项外，本发明提供了新型异戊二烯基化合物，能够有效调节炎症反应，并提供包含这些异戊二烯基化合物的药物、化妆品、化妆品和局部组合物。本发明的抗炎化合物可用于治疗或预防与炎症相关的疾病或症状。本发明的促炎化合物可用于治疗或预防与抑制炎症反应相关的疾病或症状。因此，本发明还提供了用于治疗或预防与炎症相关的疾病或症状以及用于治疗或预防与抑制炎症反应相关的疾病或症状的方法。
• ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES
  申请人：RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

  公开号：US20160263083A1

  公开（公告）日：2016-09-15

  The invention provides compounds of formula Ia, Ib and Ic: and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.

  本发明提供了Ia、Ib和Ic式化合物及其盐，其中变量如规范所述，以及包含Ia-Ic式化合物的组合物、制备这种化合物的方法以及使用这种化合物的方法，例如作为细菌RNA聚合酶的抑制剂和抗菌剂。
• Transparent liquids, in particular fabric treatment agents, comprising perfume and microcapsules with an odor modulator compound
  申请人：Henkel AG & Co. KGaA

  公开号：US10920176B2

  公开（公告）日：2021-02-16

  A liquid, transparent composition comprising microcapsules with at least one odor modulator compound, the composition also comprising at least one perfume. Even though the composition is in capsules, the transparent liquids can be produced using intense and lasting fragrances in the substrate.

  一种液态透明组合物，由含有至少一种气味调节化合物的微胶囊组成，该组合物还包括至少一种香水。即使该组合物是胶囊状的，也可以在基质中使用浓烈持久的香料来生产透明液体。
• DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS
  申请人：Cayman Chemical Company, Incorporated

  公开号：EP2874620B1

  公开（公告）日：2016-10-12

表征谱图